Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:CABA NASDAQ:ELVN NASDAQ:IMNM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$15.88+0.4%$15.75$7.28▼$16.88$2.04B1.411.11 million shs85,751 shsCABACabaletta Bio$3.16+4.8%$3.37$1.26▼$4.23$514.42M3.213.27 million shs202,621 shsELVNEnliven Therapeutics$45.89-0.5%$41.47$14.78▼$48.53$2.79B0.291.19 million shs133,662 shsIMNMImmunome$18.58+1.1%$21.77$7.96▼$27.65$2.10B2.041.35 million shs26,144 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%-0.13%+3.53%+10.55%+93.40%CABACabaletta Bio0.00%-7.38%-9.06%-5.94%+51.26%ELVNEnliven Therapeutics0.00%+32.90%+11.59%+68.42%+110.54%IMNMImmunome0.00%-1.08%-11.97%-9.72%+99.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$15.88+0.4%$15.75$7.28▼$16.88$2.04B1.411.11 million shs85,751 shsCABACabaletta Bio$3.16+4.8%$3.37$1.26▼$4.23$514.42M3.213.27 million shs202,621 shsELVNEnliven Therapeutics$45.89-0.5%$41.47$14.78▼$48.53$2.79B0.291.19 million shs133,662 shsIMNMImmunome$18.58+1.1%$21.77$7.96▼$27.65$2.10B2.041.35 million shs26,144 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%-0.13%+3.53%+10.55%+93.40%CABACabaletta Bio0.00%-7.38%-9.06%-5.94%+51.26%ELVNEnliven Therapeutics0.00%+32.90%+11.59%+68.42%+110.54%IMNMImmunome0.00%-1.08%-11.97%-9.72%+99.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.33Hold$17.259.04% UpsideCABACabaletta Bio 2.57Moderate Buy$15.50414.95% UpsideELVNEnliven Therapeutics 2.86Moderate Buy$61.5033.32% UpsideIMNMImmunome 2.85Moderate Buy$33.1780.45% UpsideCurrent Analyst Ratings BreakdownLatest CABA, ELVN, IMNM, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026IMNMImmunome WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$31.006/9/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.006/3/2026CABACabaletta Bio Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026ELVNEnliven Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $62.005/28/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $37.005/28/2026IMNMImmunome BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.005/28/2026IMNMImmunome BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.005/15/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/15/2026IMNMImmunome Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$37.00 ➝ $33.005/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/13/2026IMNMImmunome HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$283.05M7.19$1.01 per share15.61$4.41 per share3.59CABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/AELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AIMNMImmunome$6.94M299.93N/AN/A$5.75 per share3.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$287.20M$2.177.2919.78N/A99.97%26.62%19.65%7/30/2026 (Estimated)CABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)IMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)Latest CABA, ELVN, IMNM, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/7/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18$0.25+$0.07$0.25$76.98 million$77.71 million5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.085.555.01CABACabaletta BioN/A2.952.95ELVNEnliven TherapeuticsN/A40.3240.32IMNMImmunomeN/A21.6821.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CABACabaletta BioN/AELVNEnliven Therapeutics95.08%IMNMImmunome44.58%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%CABACabaletta Bio6.44%ELVNEnliven Therapeutics3.00%IMNMImmunome7.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300128.60 million112.91 millionOptionableCABACabaletta Bio50163.05 million152.55 millionOptionableELVNEnliven Therapeutics5060.90 million59.08 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableCABA, ELVN, IMNM, and AUPH HeadlinesRecent News About These CompaniesImmunome's (IMNM) Outperform Rating Reaffirmed at WedbushJune 13 at 3:28 AM | americanbankingnews.comImmunome shareholders reaffirm board, auditor and pay policiesJune 12 at 5:50 PM | tipranks.comImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid TumorsJune 11, 2026 | businesswire.comImmunome (NASDAQ:IMNM) Director Jean Jacques Bienaime Acquires 10,500 SharesJune 10, 2026 | insidertrades.comImmunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comImmunome: Varegacestat Is The Beachhead, But The ADC Engine Is The ThesisJune 9, 2026 | seekingalpha.com4 Biotech Stocks Investors Should Watch in 2026June 5, 2026 | zacks.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2026 | businesswire.comImmunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 4, 2026 | americanbankingnews.comBarclays Remains a Buy on Immunome (IMNM)June 2, 2026 | theglobeandmail.comImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingMay 30, 2026 | businesswire.comBarclays initiates coverage of Immunome (IMNM) with overweight recommendationMay 29, 2026 | msn.comImmunome to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 27, 2026 | businesswire.comPrivate Capital Advisors Inc. Has $506,000 Stock Holdings in Immunome, Inc. $IMNMMay 24, 2026 | marketbeat.comImmunome Expands Oncology Pipeline With New Phase 1 IM-1617 TrialMay 22, 2026 | tipranks.comInsider Buying: Immunome (NASDAQ:IMNM) Director Buys 5,000 Shares of StockMay 20, 2026 | insidertrades.comWhat Offers Immunome (IMNM) a Compelling Investment Opportunity?May 18, 2026 | insidermonkey.comImmunome (NASDAQ:IMNM) Stock Rating Upgraded by Wall Street ZenMay 16, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)May 15, 2026 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)May 14, 2026 | theglobeandmail.comImmunome Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCABA, ELVN, IMNM, and AUPH Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$15.88 +0.06 (+0.38%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Cabaletta Bio NASDAQ:CABA$3.16 +0.15 (+4.82%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Enliven Therapeutics NASDAQ:ELVN$45.89 -0.24 (-0.51%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Immunome NASDAQ:IMNM$18.58 +0.20 (+1.06%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
